Purchase Order 75N92E23P00236
Award Date 8/7/23
Potential Completion Date 8/7/23
Potential Value $25K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
MONTGOMRY VLG, MD 20877, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Genedx, LLC, a division of Opko Health, Inc., has been awarded a $25,000 firm fixed price purchase order by the National Institutes of Health's National Human Genome Research Institute to provide exome and genome sequencing with optional mitochondrial testing for various patients. The contract has a period of performance of just over one year, running from September 2023 through August 2024. Genedx will perform the sequencing and testing services at its laboratory location in Montgomery Village,...
- This is a purchase order contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Human Genome Research Institute (NHGRI) to Genedx, LLC, a for-profit limited liability company. The $423,160.00 firm fixed-price contract is for the NHGRI Fellows Training in Clinical Cytogenetics and Biomedical Genome and Genetics program, with a completion date of August 31, 2023. The contract was awarded on August 30, 2018 and does not have a set-aside...
- This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Human Genome Research Institute to Genedx, LLC, a subsidiary of Opko Health, Inc. The $25,000.00 firm fixed-price purchase order is for the provision of genetic testing services, including mutation analysis, exome and genome sequencing, gene panel testing, and mitochondrial testing. The contract has a completion date of June 30, 2025. Genedx is the prime...
- This firm fixed-price contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Genedx, LLC, a provider of genetic testing and diagnostic services. The $5,250 contract tasks Genedx with providing a range of genetic testing services, including mutation analysis, exome and genome sequencing, gene panel testing, and mitochondrial testing, in support of NIH's clinical research missions. This contract is not set aside for any socioeconomic...
- This federal contract award, valued at $20,000.00, was issued by the National Human Genome Research Institute (NHGRI) to Genedx, LLC, a wholly owned subsidiary of Opko Health, Inc. The contract provides for the Genedx Hereditary MDS/Leukemia Panel (T830) and Copy Number Variation (CNV) testing services to be made available to potential participants who do not otherwise have access to this genetic testing. The contract is structured as a firm fixed-price purchase order with a period of...
- This federal contract award is for medical laboratory testing services provided by Genedx, LLC to the National Institutes of Health (NIH) Clinical Center. The contract, valued at $100,000.00, is a firm fixed-price purchase order with an ultimate completion date of August 12, 2015. Genedx, a for-profit limited liability company, has been a provider of genetic testing services to the NIH, supporting various research and clinical programs, particularly at the NIH Clinical Center and the National...
- This is a firm fixed-price purchase order awarded by the National Institutes of Health (NIH) Clinical Center to Genedx, LLC, a leading provider of genetic testing and diagnostic services. The contract, valued at $75,395.00, provides for a range of genetic testing services to support NIH research and clinical programs, including mutation analysis, exome and genome sequencing, gene panel testing, and mitochondrial testing. Genedx, a wholly owned subsidiary of Opko Health, Inc., has extensive...
- This federal contract award to Genedx, LLC, doing business as Genedx, supports genetic mutation testing for the National Institutes of Health (NIH) Clinical Center. The $80,477.50 firm fixed-price purchase order has a performance period from July 2018 to July 2018. Genedx, a wholly owned subsidiary of Opko Health, Inc., is a leading provider of genetic testing and diagnostic services, specializing in comprehensive genetic analysis including mutation analysis, exome and genome sequencing, gene...
- This firm fixed-price purchase order was awarded by the Office of the Chief Operating Officer (a civilian agency), a component of the National Institutes of Health (NIH), to Genedx, LLC, a for-profit limited liability company. The $81,666 contract is for medical laboratory testing services, specifically genetic testing and diagnostic services. Genedx, a wholly owned subsidiary of Opko Health, Inc., provides comprehensive genetic testing, including mutation analysis, exome and genome...
- This federal contract award is for medical laboratory testing services and was issued by the National Institutes of Health (NIH) Clinical Center to Genedx, LLC, a leading provider of genetic testing and diagnostic services. The contract, valued at $81,410.00, is a firm fixed-price purchase order without a set-aside designation, indicating Genedx competed in the open market. Genedx operates from its facilities in Maryland and has held several Indefinite Delivery Vehicle (IDV) contracts with the...